Phase 2
Completed N=50
Saracatinib and Alcohol Drinking
Alcohol Drinking
Source: ClinicalTrials.gov NCT02955186 ↗
Enrolled (actual)
50
Serious AEs
4.0%
Results posted
Nov 2020
Primary outcomePrimary: Change in the Number of Drinks Consumed From Baseline to Day 8 (Minus Baseline) — -1.85; -2.33 drinks
Summary
The purpose of this study is to evaluate the effects of the study medication, saracatinib/AZD0530 (placebo or 125 mg/day) on alcohol drinking behavior in a laboratory setting in which participants are given an initial drink of alcohol followed by the choice to drink up to 12 more drinks over a three-hour period. The investigators hypothesize that saracatinib will reduce craving and number of drinks consumed prior to and after exposure to the initial drink of alcohol and during the three hour drinking period.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change in the Number of Drinks Consumed From Baseline to Day 8 (Minus Baseline) |
-1.85; -2.33 | — |
| PRIMARY Craving-Baseline Adjusted Total Area Under the Curve (AUC) During the Drinking Session Using the YCS |
3133; 2876 | — |
| SECONDARY Area Under the Curve (AUC) During the Drinking Session Using the Stimulation Responses to Alcohol (BAES) |
1650.8; 1607.1 | — |
| SECONDARY Area Under the Curve (AUC) During the Drinking Session Using the Sedation Responses to Alcohol (BAES) |
1149.9; 515.29 | — |
Eligibility Criteria
Inclusion Criteria
- Ages 21-50
- Able to read English at 6th grade level or higher and to complete study evaluations
- Regular alcohol drinker
Exclusion Criteria
- Individuals who are seeking alcohol treatment
- Medical conditions that would contraindicate the use of saracatinib
- Regular use of other substances
Data sourced from ClinicalTrials.gov (NCT02955186). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.